intravenous administration of oxytocin

Phase 2Small molecule

intravenous administration of oxytocin is one of 29 small molecule programs targeting Total Hip Arthroplasty. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Total Hip ArthroplastyEnrolling by invitation

Total Hip ArthroplastyPhase 2

Enrolling by invitation

Competition

Competitive Landscape

30 competitors in Total Hip Arthroplasty

#DrugCompanyPhaseTrials

Cyklokapron

JJ Molner

Approved

13 2

Fragmin

Pfizer

Approved

1 3

Naropin

FFresenius Kabi USA, LLC

Approved

9 4

Zometa

Pfizer

Approved

1 5

Medrol

Pfizer

Approved

1 6

Toradol

Roche

Approved

1 7

Decadron

AAspen Global Incorporated

Approved

5 8

Marcaine

IInnocoll

Approved

5 9

Xylocaine

MMEDRx USA, Inc.

Approved

4 10

Tylenol

KKenvue Brands

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Total Hip Arthroplasty1 trial

Efficacy of Intravenous Oxytocin to Speed Recovery After Total Hip Arthroplasty

Enrolling by invitation·WWake Forest University Health Sciences·Phase 2·NCT07430228·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for intravenous administration of oxytocin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — intravenous administration of oxytocin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for intravenous administration of oxytocin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Wake Forest University Health Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: WWake Forest University Health Sciences

intravenous administration of oxytocin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Total Hip Arthroplasty1 trial

References

Drug Info

Quick Facts

Related News